Pneumologie 2009; 63(4): 207-218
DOI: 10.1055/s-0028-1100827
Serie: Tuberkulose

© Georg Thieme Verlag KG Stuttgart · New York

Besonderheiten der Kindertuberkulose

Characteristics of Childhood TuberculosisA.  K.  Detjen1, 2 , K.  Magdorf1, 3
  • 1Klinik für Pädiatrie m.S. Pneumologie und Immunologie, Charité Universitätsmedizin, Berlin, Deutschland
  • 2Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Health Sciences, Stellenbosch University, South Africa
  • 3Abteilung für pädiatrische Pneumologie und Allergologie, Helios Klinikum Emil von Behring, Berlin
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
03. März 2009 (online)

Zusammenfassung

Während die Inzidenz der Tuberkulose in den meisten westlichen Industrieländern rückläufig ist, gehört diese Infektionskrankheit weltweit zu den häufigsten Todesursachen im Kindesalter. Kinder werden meist durch Erwachsene in ihrem direkten Umfeld infiziert. Die klinische Manifestation ist direkte Folge der Primärinfektion und spiegelt damit die Übertragungsrate innerhalb der Gesellschaft wider. Kinder mit unbehandelter Infektion bleiben ein lebenslanger Pool für spätere Erkrankung und Infektionsquellen. Prävention und Therapie der latenten Tuberkulose-Infektion sind daher grundlegende Aufgaben des Gesundheitssystems. Kinder haben nach Infektion mit Mycobacterium tuberculosis ein besonders hohes Erkrankungsrisiko. Die Krankheit manifestiert sich unterschiedlich und häufig schwerwiegender als bei Erwachsenen. Gleichzeitig ist die Diagnose der Tuberkulose im Kindesalter aufgrund der oft unspezifischen klinischen Präsentation sowie der Schwierigkeit des kulturellen Erregernachweises eine besondere Herausforderung. Der Artikel gibt einen Überblick über die Besonderheiten der Epidemiologie, Klinik, Diagnostik und Behandlung der Tuberkulose im Kindesalter.

Abstract

In spite of a decline in the western industrialised countries, tuberculosis remains one of the commonest causes of childhood mortality in the world. In most cases, children become infected by adults in their immediate environment. The clinical manifestation as a consequence of the primary infection reflects the community transmission of tuberculosis. Children with untreated infection remain a lifelong pool for future disease and therefore infectivity. Thus, prevention and therapy of latent tuberculosis infection are fundamental duties of the public health system. The risk of developing active disease following infection with Mycobacterium tuberculosis is especially high in children. Compared to adults, childhood tuberculosis manifests differently and is often more severe. At the same time, the diagnosis is complicated by the unspecific clinical presentation and difficulty of culture confirmation in children. This article gives an overview of the special features of the epidemiology, clinical presentation, diagnosis and management of childhood tuberculosis.

Literatur

  • 1 Dolin P J, Raviglione M C, Kochi A. Global tuberculosis incidence and mortality during 1990 – 2000.  Bull World Health Organ. 1994;  72 213-220
  • 2 Rekha B, Swaminathan S. Childhood tuberculosis – global epidemiology and the impact of HIV.  Ped Respir Rev. 2007;  8 99-106
  • 3 Jereb J A, Kelly G D, Porterfield D S. The epidemiology of tuberculosis in children.  Sem Pediatr Infect Dis. 1993;  4 220-231
  • 4 Nelson L J, Wells C D. Global epidemiology of childhood tuberculosis.  Int J Tuberc Lung Dis. 2004;  8 636-647
  • 5 World Health Organization .Global Tuberculosis Control: Surveillance, Planning, Financing: WHO report 2008. Geneva: World Health Organization (WHO/HTM/TB/2008.393) 2008
  • 6 Clancy L, Rieder H L, Enarson D A. et al . Tuberculosis elimination in the countries of Europe and other industrialized countries.  Eur Respir J. 1991;  4 1288-1295
  • 7 Robert Koch-Institut .Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2006. Berlin: Robert Koch-Institut 2008
  • 8 World Health Organization .Anti-Tuberculosis Drug-Resistance in the World. Report No. 4. Geneva: World Health Organization (WHO/HTM/TB/2008.394) 2008
  • 9 World Health Organization . Extensively drug-resistant tuberculosis (XDR-TB): Recommendations for prevention and control.  Wkly Epidemiol Rec. 2006;  81 430-432
  • 10 Cardona M, Bek M D, Mills K. et al . Transmission of tuberculosis from a seven-year-old child in a Sydney school.  J Paediatr Child Health. 1999;  35 375-378
  • 11 Donald P R, Fourie P B, Grange J M. Tuberculosis in childhood. JL van Schalk Publishers 1999
  • 12 Loudon R G, Spohn S K. Cough frequency and infectivity in patients with pulmonary tuberculosis.  Am Rev Respir Dis. 1969;  99 109-111
  • 13 Corbett E L, Watt C J, Walker N. et al . The growing burden of tuberculosis. Global Trends and Interactions with the HIV Epidemic.  Arch intern Med. 2003;  163 1009-1021
  • 14 Aaron L, Saadoun D, Calantroni I. et al . Tuberculosis in HIV-infected patients: a comprehensive review.  Clin Microbiol Infect. 2004;  10 388-398
  • 15 Marais B J, Gie R P, Schaaf H S. et al . The Natural History of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era.  Int J Tuberc Lung Dis. 2006;  8 392-402
  • 16 Schlossberg D. Tuberculosis and nontuberculous mycobacterial infections. Fifth Edition. McGraw-Hill Companies 2006
  • 17 Jacobsen M, Detjen A, Mueller H. et al . Clonal expansion of CD8+ effector T cells in childhood tuberculosis.  J Immunol. 2007;  179 1331-1339
  • 18 Casanova J-L, Abel L. The Human Model: A genetic dissection of immunity to infection in natural conditions.  Nature Reviews Immunology. 2004;  4 55-66
  • 19 Ulrichs T, Kaufmann S HE. Immunology and Persistence.  Issues Infect Dis. 2003;  2 112-127
  • 20 Feja K, Saiman L. Tuberculosis in children.  Clin Chest Med. 2005;  26 295-312
  • 21 Marais B J, Gie R P, Schaaf H S. et al . A proposed radiological classification of childhood intra-thoracic tuberculosis.  Pediatr Radiol. 2004;  34 886-894
  • 22 Cruz A T, Starke J R. Clinical manifestations of tuberculosis in children.  Paed Respir Rev. 2007;  8 107-117
  • 23 Romanus V, Hallander H, Wahlen P. et al . Atypical mycobacteria in extrapulmonary disease among children. Incidence in Sweden from 1969 to 1990, related to changing BCG-vaccination.  Tuber Lung Dis. 1995;  76 300-310
  • 24 Wiese-Posselt M, Siedler A, Rademacher A. et al .ESPID-Study-Group 2: incidence of nontuberculous mycobacteria (NTM) in children aged < 15 years, Germany 2002 – 2004. Tampere, Finland: ESPID Annual Meeting May 2004
  • 25 Haverkamp M H, Arend S M, Lindeboom J A. et al . Nontuberculous mycobacterial infection in children: A 2-year prospective surveillance study in the Netherlands.  Clin Infect Dis. 2004;  39 450-456
  • 26 Thegerström J, Friman V, Nylen O. et al . Clinical features and incidence of Mycobacterium avium infections in children.  Scand J Infect Dis. 2008;  40 481-486
  • 27 Lindeboom J A, Kuijper E J, Bruijnesteijn van Coppenraet E S. et al . Surgical excision versus antibiotic treatment for nontuberculous mycobacterial cervicofacial lymphadenitis in children: A Multicenter, Randomized, Controlled Trial.  Clin Infect Dis. 2007;  44 1057-1064
  • 28 Griffith D E, Aksamit T, Brown-Elliott B A. et al . An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.  Am J Respir Crit Care Med. 2007;  175 367-416
  • 29 Wallgren A. The time-table of tuberculosis.  Tubercle. 1948;  29 245-251
  • 30 Schoeman J, Mansvelt E, Springer P. et al . Coagulant and fibrinolytic status in tuberculous meningitis.  Pediatr Infect Dis J. 2007;  26 428-431
  • 31 Medical Research Council Streptomycin in Tuberculosis Trials Committee . Streptomycin treatment in tuberculous meningitis.  Lancet. 1948;  1 582-597
  • 32 Rock R B, Olin M, Baker C A. et al . Central nervous system tuberculosis: pathogenesis and clinical aspects.  Clin Microbiol Rev. 2008;  21 243-261
  • 33 Schoeman J F, Van Zyl L E, Laubscher J A. et al . Serial CT scanning in childhood tuberculous meningitis: prognostic features in 198 cases.  J Child Neurol. 1995;  10 320-329
  • 34 Schoeman J, Wait J, Burger M. et al . Long-term follow up of childhood tuberculous meningitis.  Dev Med Child Neurol. 2002;  44 522-526
  • 35 Sharma S K, Mohan A, Sharma A. et al . Miliary Tuberculosis: New Insights Into an Old Disease.  Lancet Infect Dis. 2005;  5 415-430
  • 36 Connelly Smith K. Congenital tuberculosis: a rare manifestation of a common infection.  Curr Opin Infect Dis. 2002;  15 269-274
  • 37 Cantwell M F, Shehab Z M, Costello A M. et al . Congenital Tuberculosis.  New Engl J Med. 1994;  330 1051-1054
  • 38 Ormerod P. Tuberculosis in pregnancy and the puerperium.  Thorax. 2001;  56 494-499
  • 39 Ozuah P O, Ozuah T P, Stein R EK. et al . Evaluation of a risk assessment questionnaire used to target tuberculin skin testing in children.  JAMA. 2001;  285 451-453
  • 40 Magdorf K, Detjen A K. Proposed management of childhood tuberculosis in low-incidence countries.  Eur J Pediatr. 2008;  167 927-938 Epub 2008 May 10
  • 41 Magdorf K. Tuberkulose und nicht-tuberkulöse mykobakterielle Krankheiten. In: DGPI Handbuch, Infektionen bei Kindern und Jugendlichen. 4. Auflage. München: Futuramed Verlag 2003: 699-719
  • 42 Sagebiel D, Magdorf K, Loddenkemper R. Aktuelle Information des DZK zur Tuberkulinversorgung Deutschlands.  Pneumologie. 2005;  59 236-237
  • 43 American Thoracic Society, Centers for Disease Control and Prevention . Targeted tuberculin testing, and treatment of latent tuberculosis infection.  Am J Respir Crit Care Med. 2000;  161 221-247
  • 44 Magdorf K. Tuberkulose im Kindesalter – Pathogenese, Prävention, Klinik und Therapie.  Monatsschr Kinderheilk. 2006;  154 124-132
  • 45 Haimi-Cohen Y. Skin indurations in response to tuberculin testing in patients with nontuberculous mycobacterial lymphadenitis.  Clin Infect Dis. 2001;  33 1786-1788
  • 46 Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update.  Ann Intern Med. 2008;  149 [Epub ahead of print]
  • 47 Pai M, Menzies D. Interferon-gamma release assays: what is their role in the diagnosis of active tuberculosis?.  Clin Infect Dis. 2007;  44 74-77
  • 48 Detjen A K, Keil T, Roll S. et al . Interferon-γ release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis.  Clin Infect Dis. 2007;  45 322-328
  • 49 Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part I. Latent tuberculosis.  Expert review of molecular diagnostics. 2006;  6 413-422
  • 50 Karam F, Mbow F, Fletcher H. et al . Sensitivity of IFN-gamma release assay to detect latent tuberculosis infection is retained in HIV-infected patients but dependent on HIV/AIDS progression.  PLoS ONE. 2008;  3 e1441
  • 51 Liebeschuetz S, Bamber S, Ewer K. et al . Diagnosis of tuberculosis in South African children with a T-cell-bases assay: a prospective cohort study.  Lancet. 2004;  365 97-98
  • 52 Mandalakas A M, Hesseling A C, Chegou N N. et al . High level of discordant IGRA results in HIV-infected adults and children.  Int J Tuberc Lung Dis. 2008;  12 417-423
  • 53 Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research.  Ann Intern Med. 2007;  146 350-354
  • 54 Diel R, Loddenkemper R, Meywald-Walter K. et al . Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis.  Am J Respir Crit Care Med. 2008;  177 1164-1170
  • 55 Hill P C, Jackson-Sillah D J, Fox A. et al . Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts.  PLoS ONE. 2008;  3 e1379
  • 56 Mazurek G H, Jereb J, Lobue P. et al . Guidelines for using QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States.  MMWR Recomm Rep. 2005;  54 49-55
  • 57 National Institute for Health and Clinical Excellence .Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. Available at: www.nice.org.uk 2006
  • 58 Haute Autorité de santé .Test de détéction de la production d'interferon-γ pour le diagnosis des infection tuberculeuses. Available at: www.has-santé.fr 2006
  • 59 Diel R, Nienhaus A, Lange C. et al . Cost-optimization of screening for latent tuberculosis in close contacts.  Eur Respir J. 2006;  28 35-44
  • 60 Diel R, Forssbohm M, Loytved G. et al . Empfehlungen für die Umgebungsuntersuchungen bei Tuberkulose.  Pneumologie. 2007;  61 440-455
  • 61 Canadian Tuberculosis Committee .Interferon gamma release assays for latent tuberculosis infection. Canada Communicable Disease Report 2007
  • 62 Doherty T M, Demissie A, Menzies D. et al . VACSEL Study Group. Effect of sample handling on analysis of cytokine responses to Mycobacterium tuberculosis in clinical samples using ELISA, ELISPOT and quantitative PCR.  J Immunol Meth. 2005;  298 129-141
  • 63 Meier T, Eulenbruch H P, Wrighton-Smith P. et al . Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice.  Eur J Clin Microbiol Infect Dis. 2005;  24 529-536
  • 64 Dinnes J, Deeks J, Kunst H. et al . A systematic review of rapid diagnostic tests for the detection of tuberculosis.  Health Technol Assess. 2007;  11 1-196
  • 65 Rüsch-Gerdes S, Hillemann D. Moderne mykobakteriologische Labordiagnostik.  Pneumologie. 2008;  62 533-540
  • 66 Zar H J, Hanslo D, Apolles P. Induced sputum versus gastric lavage for microbiological confirmation of pulmonary tuberculosis in infants and young children: a prospective study.  Lancet. 2005;  365 130-134
  • 67 Starke J R. Pediatric tuberculosis: time for a new approach.  Tuberculosis. 2003;  5 594-603
  • 68 Steingart K R, Henry M, Hopewell P C. et al . Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review.  Lancet Infect Dis. 2006;  6 570-581
  • 69 Marais B J, Hesseling A C, Gie R P. et al . The bacteriologic yield in children with intrathoracic tuberculosis.  Clin Infect Dis. 2006;  42 69-71
  • 70 Ling D I, Flores L L, Riley L W. et al . Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression.  PLoS ONE. 2007;  3 (2) e1536 doi 0.1371/journal.pone.0001536
  • 71 Steingart K R, Henry M, Laal S. et al . Commercial serological antibody detection tests for the diagnosis of pulmonary tuberculosis: a systematic review.  PLoS Med. 2007;  4 e202
  • 72 World Health Organization .Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2006 WHO/HTM/ TB/2006.371
  • 73 Broekmans J F, Migliori G B, Rieder H L. et al . European framework for tuberculosis control and elimination in countries with a low incidence.  Eur Respir J. 2002;  19 765-775
  • 74 Colditz G A, Berkey C S, Mosteller F. et al . The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature.  Pediatrics. 1995;  96 29-35
  • 75 Davies P DO. Clinical Tuberculosis. Arnold Publishers. Third Edition 2003
  • 76 Soysal A, Millington K A, Bakir M. et al . Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study.  Lancet. 2005;  366 1443-1451
  • 77 Infuso A, Falzon D. European survey of BCG vaccination policies and surveillance in children, 2005.  Euro Surveill. 2006;  11 6-11
  • 78 Ständige Impfkommission am Robert Koch Institut .Impfempfehlungen der Ständigen Impfkommission (STIKO) Stand März 1998. Epidemiologisches Bulletin. Robert Koch Institut 15/98: 101-112
  • 79 Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose . Richtlinien zur medikamentösen Behandlung der Tuberkulose im Erwachsenen- und Kindesalter.  Pneumologie. 2001;  55 494-511
  • 80 Comstock G W, Caras G J, Koplan J P. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?.  Int J Tuberc Lung Dis. 1999;  3 847-850
  • 81 Ormerod L P. Rifampicin ad isoniazide prophylactic chemotherapy for tuberculosis.  Arch Dis Child. 1998;  78 169-171
  • 82 Ena J, Valls V. Shourt course therapy with rifampicin plus isonoazid, compared with standard therapy with isoniazid for latent tuberculosis infection: a meta-analysis.  Clin Infect Dis. 2005;  40 670-676
  • 83 Rennie T W, Bothamley G H, Engova D. et al . Patient choice promotes adherence in preventive treatment for latent tuberculosis.  Eur Respir J. 2007;  30 728-735
  • 84 Spyridis N P, Spyridis P G, Gelesme A. et al . The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study.  Clin Infect Dis. 2007;  45 715-722
  • 85 Thee S, Detjen A K, Quarcoo D. et al . Ethambutol in paediatric tuberculosis: aspects of ethambutol serum concentration, efficacy and toxicity in children.  Int J Tuberc Lung Dis. 2007;  11 965-971
  • 86 Thee S, Detjen A K, Wahn U. et al . Pyrazinamide serum levels in childhood tuberculosis.  Int J Tuberc Lung Dis. 2008;  12 1099-1101
  • 87 American Thoracic Society/Centers for Disease Control and Prevention/Infectious Disease society of America . Treatment of tuberculosis.  Am J Resp Crit Care Med. 2003;  167 63-662
  • 88 Ellard G A, Humphries M J, Allen B W. Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis.  Am Rev Respir Dis. 1993;  148 650-655
  • 89 Donald P R, Seifart H I. Cerebrospinal fluid concentrations of ethionamide in children with tuberculous meningitis.  J Pediatr. 1989;  115 483-486
  • 90 Prasad K, Volmink J, Menon G R. Steroids for treating tuberculous meningitis. The Cochrane Database of Systematic Reviews 2000, Issue 3. Art. No.: CD002244. DOI: 10.1002/14 651 858.CD002244
  • 91 Schoeman J F, Van Zyl L E, Laubscher J A. et al . Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis.  Pediatrics. 1997;  99 226-231
  • 92 Thwaites G E, Macmullen-Price J, Tran T H. et al . Serial MRI to determine the effect of dexamethasone on the cerebral pathology of tuberculous meningitis: an observational study.  Lancet Neurol. 2007;  6 230-236
  • 93 Dooley D P, Carpenter J L, Rademacher S. Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature.  Clin Infect Dis. 1997;  25 872-887
  • 94 Jain A K, Dhammi I K. Tuberculosis of the spine: a review.  Clin Orthop Relat Res. 2007;  460 39-49
  • 95 Ferebee S H. Controlled chemoprophylaxis trials in tuberculosis: A general review.  Bibl Tuberc. 1970;  26 28-106
  • 96 Otto H S, Magdorf K. Aktueller Stand der antituberkulösen Chemotherapie im Kindesalter.  Prax Pneumol. 1981;  35 588-595
  • 97 Ravenscroft A, Schoeman J F, Donald P R. Tuberculous granulomas in childhood tuberculous meningitis: radiological features and course.  J Trop Pediatr. 2001;  47 5-12
  • 98 Schoeman J F, Fieggen G, Seller N. et al . Intractable intracranial tuberculous infection responsive to thalidomide: report of four cases.  J Child Neurol. 2006;  21 301-308
  • 99 Sneag D B, Schaaf H S, Cotton M F. et al . Failure of chemoprophylaxis with standard antituberculosis agents in child contacts of multidrug-resistant tuberculosis.  Pediatr Infect Dis J. 2007;  26 1142-1146
  • 100 Katiyar S K, Bihari S, Prakash S. et al . A randomized controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis.  Int J Tuberc Lung Dis. 2008;  12 139-145

1 Leider wird die Durchführung eines IGRA in Deutschland bisher nicht von den Krankenkassen übernommen („IGEL-Leistung”).

Bisher erschienene Beiträge aus dieser Serie

Dr. med. Klaus Magdorf

Abteilung für pädiatrische Pneumologie und Allergologie, Helios Klinikum Emil von Behring, Standort Campus Benjamin Franklin/Charité

Hindenburgdamm 30

12200 Berlin

eMail: klaus.magdorf@charite.de

eMail: anne.detjen@charite.de

    >